Hormonal
Succinate signaling via the SUCNR1 receptor is required for strength gains from resistance training, as blocking this pathway compromises training-induced grip strength improvements despite enhancing endurance capacity.
For strength training, your body uses succinate signaling to build muscle and neural adaptations. You don't need to supplement succinate; just perform progressive resistance training. The paper suggests that if you were to block this specific pathway, you would lose strength gains, so ensure your training is consistent and progressive to naturally stimulate this mechanism.
training-induced gains in grip strength were completely compromised in SUNCR1 KOs. In line with these observations, training resulted in increased neural-specific tubulin staining only in WT mice, while SUNCR1 KOs displayed downregulated fast MyHC isoforms as well as proteins involved in ECM organization
Why this rating
Based on mouse knockout models; human relevance is inferred.
Source
The Role of the Skeletal Muscle Secretome in Mediating Endurance and Resistance Training Adaptations
Aurel B. Leuchtmann et al. · Frontiers in Physiology · 2021
DOI 10.3389/fphys.2021.709807
More from this paper
- Skeletal muscle-derived VEGF, induced by endurance exercise via PGC-1α, mediates training-induced capillarization, enhancing oxygen and substrate delivery to muscle tissue.Good
- Endurance training adaptations, including visceral fat reduction and cardiac remodeling, are mediated by muscle-secreted IL-6, as blocking IL-6 receptors impairs these specific structural adaptations without affecting peak endurance capacity (VO2peak).Moderate
- Skeletal muscle-derived myonectin confers protection against ischemia-reperfusion injury in the heart, as endurance training reduces infarct size in wild-type mice but not in myonectin-deficient mice.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →